Citius Pharmaceuticals, Inc. CTXRW 深 滬
等待開盤 03-26 09:30:00 美东时间
0.1441
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.1441
- 總市值 1941.04万
- 52周最高 1.00
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.012
- 委 比 0.00%
- 總股本 1.35亿
- 歷史最高 2.89
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.012
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Citius Oncology Announces Topline Results From Investigator‑Initiated Phase 1 Trial Of LYMPHIR Administered Prior To Commercial CD19‑Directed CAR‑T Therapy In High‑Risk DLBCL; Co Says LYMPHIR Was Well-Tolerated With No Dose-Limiting Toxicities Observed
Topline data of investigator‑initiated study at the University of Minnesota and City of Hope demonstrates 86% overall response rate (OR), including 57% complete response (CR) and 29% partial response (PR)LYMPHIR was
03-04 22:18
Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program
Non-dilutive capital supports continued execution and value creation CRANFORD, N.J., Feb. 24, 2026 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CT...
02-24 21:00
Citius Pharmaceuticals Q1 Earnings Report: What Investors Need to Know
Citius Pharmaceuticals (NASDAQ:CTXR) reported its Q1 earnings results on Friday...
02-13 22:14
Citius Pharmaceuticals reports first revenue of $3.9 mln
Citius Pharmaceuticals reports first revenue of $3.9 mln Overview Biopharmaceutical firm reported first revenue of $3.9 mln from LYMPHIR launch in Q1 2026 Net loss for Q1 2026 was $8.2 mln, with basic EPS of -$0.38 Citius Oncology launched LYMPHIR for cutaneous T-cell lymphoma in December 2025 Outlo
02-13 21:08
Citius Pharma Q1 stock-based compensation expense rises to USD 3.56 million, up 97%
Citius Pharma Q1 stock-based compensation expense rises to USD 3.56 million, up 97% Citius Pharmaceuticals Inc. reported its earnings for the three months ended December 31, 2025. The company posted interest income of USD 0.05 million for the quarter. Interest expense totaled USD 0.16 million for th
02-13 21:01
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
Company reports $3.9 million in revenue generated from initial sales in December 2025 and provides first fiscal quarter 2026 financial results CRANFORD, N.J., Feb. 13, 2026 /PRNewswire/ -- C...
02-13 21:00
Citius Pharmaceuticals (CTXR) Surges 22% After Hours — Here's Why
Citius Pharmaceuticals shares jumped 22.12% after hours following the commercial launch of its LYMPHIR therapy and a fiscal 2025 business update.
2025-12-24 14:56
BRIEF-Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results And Provides Business Update
Dec 23 (Reuters) - Citius Pharmaceuticals Inc CTXR.O: CITIUS PHARMACEUTICALS, INC. REPORTS FISCAL YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Source text: ID:nPnXZrKa Further company cove...
2025-12-24 06:47
Citius Pharmaceuticals GAAP EPS of -$3.38
Citius Pharmaceuticals press release (CTXR): FY GAAP EPS of -$3.38. Cash and cash equivalents of $4.3 million as of September 30, 2025; Citius Pharma did not report revenues for the year; R&D expenses...
2025-12-24 05:35
Citius Oncology announces $18 million registered direct offering
Citius Oncology (CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals (CTXR), announced on Tuesday that it has entered into a definitive agreement with a single healthcare-focused investor...
2025-12-09 21:49
